arrows arrow-right arrow-left menu search rss youtube linkedin twitter facebook instagram arrow-play linkedIn
Dr. Sridhar Jaligama

Dr. Sridhar Jaligama, Research Scientist

Dr. Sridhar Jaligama joined Battelle Life Science Research in November 2016. As a Research Scientist on the Inhalation Toxicology team, he supports ongoing non-clinical toxicology and safety assessment studies for the National Toxicology Program (NTP) as well as industrial and pharmaceutical clients. Sridhar brings eight years of toxicology research experience through his doctoral and postdoctoral work. At Battelle, Sridhar supports ongoing studies for the NTP to identify the effects of inhaled chemicals, particulates and toxins on body systems. He also supports studies for companies seeking product registration for new tobacco and nicotine products such as e-cigarettes.
Dr. Joshua Allen

Dr. Joshua Allen, Research Scientist

Dr. Joshua Allen is working to bring new insights into the exposure effects of inhaled contaminants, tobacco and other airborne materials. A Research Scientist on the Inhalation Toxicology team, Joshua supports Battelle’s work on the National Toxicology Program (NTP) as well as studies on emerging tobacco products. At Battelle, Joshua is focusing on inhalation toxicology for NTP and for required regulatory studies for registration of new tobacco and nicotine products, including e-cigarettes. He may also support preclinical safety testing for inhaled pharmaceuticals.
Dr. Vijay Kale

Dr. Vijay Kale, Principal Research Scientist

Dr. Vijaykumar (Vijay) Kale is working to bring better and safer drugs to market. His long-term goal is to find methods that make pre-clinical toxicology work more efficient and accurate for drug developers. Vijay joined Battelle in September 2015 as a Principal Research Scientist on the Battelle Toxicology team. He brings more than six years of experience as a Study Director in non-clinical drug safety evaluation of small molecules and biopharmaceuticals. His experience includes safety evaluation work for Lipaglyn, a drug used for treating diabetic dyslipidemia or hypertriglyceridemia, and VaxiFlu-S, India’s first H1N1 vaccine—both now on the market. He has extensive experience designing and conducting both in vitro and in vivo toxicology studies for pre-clinical trials of small molecule and biopharmaceutical drug candidates. Some of his current work is part of the National Toxicology Program, a U.S. Department of Health and Human Services effort to find better ways to identify and predict the mechanisms that cause adverse reactions to drugs and other chemicals.
Eve Mylchreest, Ph.D.

Eve Mylchreest, Ph.D., Research Leader

Eve Mylchreest, Ph.D., has deep expertise in the area of developmental and reproductive toxicology (DART) that is invaluable to our government, industrial and pharmaceutical clients. In her role as Research Leader, she is focused on expanding Battelle’s capabilities in these areas. Eve has more than 15 years of experience as a Study Director and more than 20 years of experience in reproductive and developmental toxicology. Her work on the effects of di(n-butyl) phthalate on male reproductive development was pivotal in the risk assessment of di(n-butyl) phthalate by the National Toxicology Program. In addition to leading research studies for our commercial clients, Eve provides ongoing support for the National Toxicology Program. Her work will help the NTP determine the effects of pre-natal and post-natal exposure to certain chemicals on development.
Dr. Amy Zmarowski

Dr. Amy Zmarowski, Principal, Research Scientist

Dr. Amy Zmarowski is a Principal Research Scientist on Battelle's Life Science Research team. Amy brings extensive experience in developmental neurotoxicology and developmental and reproductive toxicology. She is helping to expand Battelle’s neurobehavioral capabilities for non-clinical toxicology and safety assessment. Amy provides leadership for neurobehavioral studies and help to expand the capabilities of the team. She also supports Battelle’s work with the National Toxicology Program, an ongoing Department of Health and Human Services program that coordinates toxicology research and testing for thousands of chemicals with potential human health concern. 
Dr. Yun Li

Dr. Yun Li, Principal Scientist

As a Principal Scientist, Yun Li puts her experience in virology and microbiology to work to develop new bioassays and conduct efficacy studies of novel drugs and vaccines. Yun is a molecular biologist with extensive research background in molecular virology, immunology, microbiology and biochemistry. She has worked in both academic and industry settings. Much of her previous research focused on the study of HIV replication and development of potential vaccines. At Battelle, Yun is applying this background to help our client companies with drug discovery. Much of her work is focused on developing cell-based immunoassays to evaluate immune response to candidate vaccines against viral infections, including alphavirus and filovirus. Her broad prior experiences with a wide range of bacteria and viruses give her an ideal background for helping pharmaceutical companies discover novel therapies and vaccines.

Dr. Daniel Sanford, Senior Research Leader

Dr. Daniel Sanford is an expert in working with deadly diseases. Over his career, he’s led safety and efficacy studies for medical countermeasures against anthrax, melioidosis, botulism, bubonic plague and many other pathogens and biological warfare agents. A Senior Research Scientist and Study Director at the Battelle Biomedical Research Center (BBRC), Dan conducts safety and efficacy studies required to bring new therapies and vaccines to market. His background includes extensive experience in bacterial pathogenesis, medical countermeasure discovery, infectious disease/containment lab research and animal model development. Much of his work is conducted under the FDA Animal Rule; Dan was involved in the licensure of the very first product (Raxibacumab) for which the effectiveness was based solely on efficacy studies in animals. Since then, Dan has directed model development and efficacy studies designed to test vaccines and therapies againstBacillus anthracis, Botulinum Neurotoxin, Ricin, Burkholderia pseudomallei, Burkholderia mallei, and Yersinia pestis.
Dr. Barney Sparrow

Dr. Barney Sparrow, Principal Investigator

Dr. Barney Sparrow is the Principal Investigator for Battelle’s work on the National Institute of Environmental Health Science’s National Toxicology Program (NTP). In his this role, he is responsible for oversight and direction of in vivo toxicology research that will provide critical insights into the toxicological profiles and potential human health impacts of dozens of chemicals that are already in widespread use. As the Principal Investigator for the NTP, Barney serves as the main point of contact for the National Institute of Environmental Health and other partner agencies and contractors, and oversees all Battelle work conducted as part of the Support of the Research Effort to Evaluate the Toxic and Carcinogenic Potential of Test Agents contract. Barney also currently serves as the Principal Investigator for the Therapeutics for Rare and Neglected Diseases (TRND) and Bridging Interventional Development Gaps (BrIDGs) programs, which focus on “orphan drugs” to treat serious but rare diseases that do not have the market potential to attract private investment.
Dr. Dinelia Rivera-Burgos

Dr. Dinelia Rivera-Burgos, Principal Research Scientist

Dr. Dinelia Rivera-Burgos applies her analytical and bioanalytical expertise to develop, optimize and quantify new methods and assays for highly toxic substances. Dinelia joined the Battelle team in February 2016 as a Principal Research Scientist. She brings extensive analytical expertise with particular specialization in chromatography, mass spectrometry, proteomics and metabolomics. In her role at Battelle, she is primarily focused on development and validation of new assays for chemical agents and other highly toxic substances. Much of her work will supports Battelle’s ongoing projects for the Department of Defense (DoD), in particular, development of new therapies and vaccines to protect soldiers from chemical and biological weapons.
Dr. Jill Harvilchuck

Dr. Jill Harvilchuck, Research Leader

Chemical warfare agents and other toxins present tremendous dangers for military personnel working in war zones. Dr. Jill Harvilchuck is working to bring new medical countermeasures to market to better protect soldiers and civilians. Jill is Research Leader for the Highly Toxic Materials group at the Battelle Biomedical Research Center (BBRC). Her work focuses primarily on development of countermeasures for chemical warfare agents such as nerve agents. Currently, she is leading a project to study the efficacy of pyridostigmine bromide for use as a pre-treatment for exposure to various chemical agents. Jill’s studies could lead to expanded licensure so it could be approved for use against other chemical agents. She is also leading a project for the use of scopolamine as a potential post-treatment adjunct for nerve agent exposure. Because the compounds she works with are so toxic, most of the work Jill does is conducted under the FDA animal rule, an alternate licensure pathway used in cases where it is not feasible or ethical to conduct efficacy studies on humans.
Dr. Rachel Spurbeck

Dr. Rachel Spurbeck

Dr. Rachel Spurbeck brings a new focus on molecular diagnostics to the Battelle Applied Genomics team. Rachel’s research background, which includes experience in forensic and diagnostic applications of next-generation sequencing, makes her uniquely suited to support the next stage of growth for Battelle Applied Genomics. Rachel is focused on expanding Battelle’s molecular diagnostic capabilities. She also supports continued development of Battelle’s forensic genomic efforts, including support of ExactID™.